Company Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:15:00 2025-06-18 EDT			5-day change	1st Jan Change
108.00 ^USD	0.00%		-3.61%	+16.92%

06-19	Global markets live: Microsoft, Gilead Sciences, Ford Motor, Vodafone, UBS…
06-19	Analyst recommendations: Lululemon, Micron, Carnival Corp, UnitedHealth…

Business description: Gilead Sciences, Inc.

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Number of employees: 17,600

Sales by Activity: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovery, Development and Commercialization of Innovative Medicines	24.69B	27.3B	27.28B	27.12B	28.75B

See all business segments

Geographical breakdown of sales: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	18.22B	19.27B	18.88B	19.44B	20.59B
Europe	4.14B	4.87B	4.47B	4.31B	4.63B
Rest of World	2.34B	3.16B	3.93B	3.37B	3.53B

See all geographic segments

Executive Committee: Gilead Sciences, Inc.

Manager	Title	Age	Since
Daniel O'Day CEO	Chief Executive Officer	60	2019-02-28
Andrew Dickinson DFI	Director of Finance/CFO	55	2019-10-31
Dietmar Berger CTO	Chief Tech/Sci/R&D Officer	-	2025-01-01
Jacquie Ross IRC	Investor Relations Contact	-	2020-12-31
Robert Cook PRN	Corporate Officer/Principal	66	2012-02-29

See GILEAD SCIENCES, INC. governance

Composition of the Board of Directors: Gilead Sciences, Inc.

Director	Title	Age	Since
Kelly Kramer BRD	Director/Board Member	57	2016-08-18
Jacqueline Barton BRD	Director/Board Member	72	2017-12-31
Harish M. Manwani BRD	Director/Board Member	71	2018-05-08
Daniel O'Day CHM	Chairman	60	2019-02-28
Sandra Horning BRD	Director/Board Member	76	2020-01-27
Javier Rodriguez BRD	Director/Board Member	54	2020-06-14
Anthony Welters BRD	Director/Board Member	70	2020-10-16
Jeffrey Bluestone BRD	Director/Board Member	71	2020-12-06
Ted Love BRD	Director/Board Member	66	2024-01-31

Composition of the Board of Directors

Shareholders: Gilead Sciences, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.426 %	117,470,825	9.426 %	12 931 M $
BlackRock Advisors LLC 6.807 %	84,831,105	6.807 %	9 338 M $
STATE STREET CORPORATION 4.776 %	59,523,675	4.776 %	6 552 M $
Fidelity Management & Research Co. LLC 4.694 %	58,499,955	4.694 %	6 440 M $
Capital Research & Management Co. (Global Investors) 4.382 %	54,610,370	4.382 %	6 012 M $

List of GILEAD SCIENCES, INC. shareholders

Holdings: Gilead Sciences, Inc.

Name	Equities	%	Valuation
GALAPAGOS NV 25.35%	16,707,477	25.35%	486,697,493 $
ARCELLX, INC. 12.43%	6,720,803	12.43%	417,093,034 $
ARCUS BIOSCIENCES, INC. 29.69%	31,424,760	29.69%	280,623,107 $
ASSEMBLY BIOSCIENCES, INC. 34.76%	2,209,471	34.76%	31,264,015 $
MERUS N.V. 0.66%	452,527	0.66%	25,373,189 $
TANGO THERAPEUTICS, INC. 4.52%	4,854,443	4.52%	10,776,863 $
KYVERNA THERAPEUTICS, INC. 9.56%	4,126,119	9.56%	10,521,603 $
XILIO THERAPEUTICS, INC. 19.9%	9,105,451	19.9%	9,742,833 $
HOOKIPA PHARMA INC. 19.43%	1,875,945	19.43%	2,982,753 $
HOOKIPA PHARMA INC. 3.87%	723,273	3.87%	2,097,492 $

Company details: Gilead Sciences, Inc.

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com

Group companies: Gilead Sciences, Inc.

Name	Category and Sector
Gilead Sciences Ireland UC Gilead Sciences Ireland UC Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Sciences Ireland UC engages in discovering, developing, and delivering innovative therapeutics for life-threatening diseases. The company is based in Carrigtwohill, Ireland.	Pharmaceuticals: Major
Gilead Therapeutics A1 Unlimited Co. Gilead Therapeutics A1 Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The company is located in Ireland.	Pharmaceuticals: Major

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GILEAD SCIENCES, INC.	0.00%	-3.61%	+71.02%	+84.52%	134B
ELI LILLY AND COMPANY	-0.78%	-3.33%	-11.94%	+169.86%	705B
JOHNSON & JOHNSON	-1.08%	-3.79%	+3.49%	-11.05%	363B
NOVO NORDISK A/S	+1.22%	-5.93%	-50.38%	+30.75%	331B
ABBVIE INC.	+0.01%	-3.60%	+8.25%	+34.14%	328B
ROCHE HOLDING AG	+0.35%	-4.62%	+4.08%	-14.29%	254B
NOVARTIS AG	+0.25%	-2.92%	+1.37%	+20.55%	228B
ASTRAZENECA PLC	+0.04%	-4.33%	-14.49%	+6.33%	220B
MERCK & CO., INC.	+1.29%	-3.09%	-38.05%	-6.30%	199B
AMGEN INC.	-0.19%	-2.62%	-5.39%	+23.34%	156B
Average	+0.11%	-2.93%	-3.20%	+33.78%	291.78B
Weighted average by Cap.	-0.05%	-3.20%	-7.49%	+52.52%